Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Metabolic syndrome is a group of metabolic abnormalities associated with increased cardiovascular and mortality risks. Glucocorticoid excess has been linked to the development of metabolic syndrome. Intracellular glucocorticoid levels are regulated by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1), a key enzyme that converts inert cortisone to active cortisol. To counter the unfavorable metabolic effects of glucocorticoids in certain tissues, 11beta-HSD-1 inhibitors are being investigated for their potential in the treatment of insulin resistance and other aspects of metabolic syndrome. Several different classes of 11beta-HSD-1 inhibitors are currently under investigation by multiple pharmaceutical companies, highlighting the encouraging progress made in this field.
Wang
Minghan
M
Amgen Inc, Department of Metabolic Disorders, One Amgen Center Drive, Mail Stop 29-1-A, Thousand Oaks, CA 91320, USA. mwang@amgen.com
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors*; D000818:Animals; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000188:drug therapy*; D010913:Pituitary-Adrenal System / Q000187:drug effects
D004791:Enzyme Inhibitors; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D006854:Hydrocortisone